Home Healthcare Biotechnology Imaging Biomarkers Market

Imaging Biomarkers Market Size, Share & Trends Analysis Report By Type (Anatomical biomarkers, Functional biomarkers, Molecular/Nuclear Biomarkers, Quantitative Imaging Biomarkers, Others), By Technology (Positron Emission Tomography (PET), Ultrasound, Magnetic Resonance Imaging, Computed Tomography (CT), Single-Photon Emission Computerized Tomography (SPECT), Others), By Application (Diagnostics, Drug Discovery & Development, Personalized Medicine, Disease Risk Assessment, Others), By End User (Hospitals, Diagnostic/imaging centers, Pharmaceutical and Biotech Companies, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: December 10, 2025 | Author: Debashree B | Format: | Report Code: SR7507DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Imaging Biomarkers Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Anatomical biomarkers
    2. Functional biomarkers
    3. Molecular/Nuclear Biomarkers
    4. Quantitative Imaging Biomarkers
    5. Others
  2. Imaging Biomarkers Market, By Technology 2022-2034 (USD MILLION/ Units)
    1. Positron Emission Tomography (PET)
    2. Ultrasound, Magnetic Resonance Imaging
    3. Computed Tomography (CT)
    4. Single-Photon Emission Computerized Tomography (SPECT)
    5. Others
  3. Imaging Biomarkers Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Diagnostics
    2. Drug Discovery & Development
    3. Personalized Medicine
    4. Disease Risk Assessment
    5. Others
  4. Imaging Biomarkers Market, By End User 2022-2034 (USD MILLION/ Units)
    1. Hospitals
    2. Diagnostic/imaging centers
    3. Pharmaceutical and Biotech Companies
    4. Others
  5. Regional Imaging Biomarkers Market
    1. North America
      1. North America Imaging Biomarkers Market By Type 2022-2034 (USD MILLION/ Units)
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
      2. North America Imaging Biomarkers Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Positron Emission Tomography (PET)
        2. Ultrasound, Magnetic Resonance Imaging
        3. Computed Tomography (CT)
        4. Single-Photon Emission Computerized Tomography (SPECT)
        5. Others
      3. North America Imaging Biomarkers Market By Application 2022-2034 (USD MILLION/ Units)
        1. Diagnostics
        2. Drug Discovery & Development
        3. Personalized Medicine
        4. Disease Risk Assessment
        5. Others
      4. North America Imaging Biomarkers Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Diagnostic/imaging centers
        3. Pharmaceutical and Biotech Companies
        4. Others
      5. U.S.
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      6. Canada
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
    2. Europe
      1. Europe Imaging Biomarkers Market By Type 2022-2034 (USD MILLION/ Units)
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
      2. Europe Imaging Biomarkers Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Positron Emission Tomography (PET)
        2. Ultrasound, Magnetic Resonance Imaging
        3. Computed Tomography (CT)
        4. Single-Photon Emission Computerized Tomography (SPECT)
        5. Others
      3. Europe Imaging Biomarkers Market By Application 2022-2034 (USD MILLION/ Units)
        1. Diagnostics
        2. Drug Discovery & Development
        3. Personalized Medicine
        4. Disease Risk Assessment
        5. Others
      4. Europe Imaging Biomarkers Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Diagnostic/imaging centers
        3. Pharmaceutical and Biotech Companies
        4. Others
      5. U.K.
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      6. Germany
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      7. France
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      8. Spain
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      9. Italy
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      10. Russia
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      11. Nordic
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      12. Benelux
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      13. Rest of Europe
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
    3. APAC
      1. APAC Imaging Biomarkers Market By Type 2022-2034 (USD MILLION/ Units)
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
      2. APAC Imaging Biomarkers Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Positron Emission Tomography (PET)
        2. Ultrasound, Magnetic Resonance Imaging
        3. Computed Tomography (CT)
        4. Single-Photon Emission Computerized Tomography (SPECT)
        5. Others
      3. APAC Imaging Biomarkers Market By Application 2022-2034 (USD MILLION/ Units)
        1. Diagnostics
        2. Drug Discovery & Development
        3. Personalized Medicine
        4. Disease Risk Assessment
        5. Others
      4. APAC Imaging Biomarkers Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Diagnostic/imaging centers
        3. Pharmaceutical and Biotech Companies
        4. Others
      5. China
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      6. Korea
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      7. Japan
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      8. India
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      9. Australia
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      10. Taiwan
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      11. South East Asia
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      12. Rest of Asia-Pacific
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
    4. Middle East and Africa
      1. Middle East and Africa Imaging Biomarkers Market By Type 2022-2034 (USD MILLION/ Units)
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
      2. Middle East and Africa Imaging Biomarkers Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Positron Emission Tomography (PET)
        2. Ultrasound, Magnetic Resonance Imaging
        3. Computed Tomography (CT)
        4. Single-Photon Emission Computerized Tomography (SPECT)
        5. Others
      3. Middle East and Africa Imaging Biomarkers Market By Application 2022-2034 (USD MILLION/ Units)
        1. Diagnostics
        2. Drug Discovery & Development
        3. Personalized Medicine
        4. Disease Risk Assessment
        5. Others
      4. Middle East and Africa Imaging Biomarkers Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Diagnostic/imaging centers
        3. Pharmaceutical and Biotech Companies
        4. Others
      5. UAE
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      6. Turkey
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      7. Saudi Arabia
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      8. South Africa
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      9. Egypt
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      10. Nigeria
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      11. Rest of MEA
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
    5. LATAM
      1. LATAM Imaging Biomarkers Market By Type 2022-2034 (USD MILLION/ Units)
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
      2. LATAM Imaging Biomarkers Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Positron Emission Tomography (PET)
        2. Ultrasound, Magnetic Resonance Imaging
        3. Computed Tomography (CT)
        4. Single-Photon Emission Computerized Tomography (SPECT)
        5. Others
      3. LATAM Imaging Biomarkers Market By Application 2022-2034 (USD MILLION/ Units)
        1. Diagnostics
        2. Drug Discovery & Development
        3. Personalized Medicine
        4. Disease Risk Assessment
        5. Others
      4. LATAM Imaging Biomarkers Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Diagnostic/imaging centers
        3. Pharmaceutical and Biotech Companies
        4. Others
      5. Brazil
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      6. Mexico
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      7. Argentina
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      8. Chile
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      9. Colombia
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
      10. Rest of LATAM
        1. Anatomical biomarkers
        2. Functional biomarkers
        3. Molecular/Nuclear Biomarkers
        4. Quantitative Imaging Biomarkers
        5. Others
        6. Positron Emission Tomography (PET)
        7. Ultrasound, Magnetic Resonance Imaging
        8. Computed Tomography (CT)
        9. Single-Photon Emission Computerized Tomography (SPECT)
        10. Others
        11. Diagnostics
        12. Drug Discovery & Development
        13. Personalized Medicine
        14. Disease Risk Assessment
        15. Others
        16. Hospitals
        17. Diagnostic/imaging centers
        18. Pharmaceutical and Biotech Companies
        19. Others
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.